Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Алгоритм терапии у больных метастатическим кастрационно-рефрактерным раком предстательной железы: современные подходы и перспективы
Алгоритм терапии у больных метастатическим кастрационно-рефрактерным раком предстательной железы: современные подходы и перспективы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Рак предстательной железы (РПЖ) является одной из наиболее актуальных проблем современной онкоурологии. Больные кастрационно-рефрактерным РПЖ (КРРПЖ) представляют собой чрезвычайно гетерогенную группу пациентов, поэтому терапевтический подход должен быть индивидуализирован в каждом конкретном случае. Терапевтические опции могут включать применение гормональной терапии 2-й линии, химиотерапии, вакцинотерапии, использование таргетных препаратов и радиофармпрепаратов. Четких рекомендаций по выбору того или иного препарата в настоящее время не существует. В статье представлен обзор возможных методов терапии у данного тяжелого контингента больных, приведены рекомендации по использованию того или иного препарата в зависимости от ряда прогностических факторов.
Ключевые слова: кастрационно-рефрактерный рак предстательной железы, химиотерапия, гормональная терапия, алгоритм лечения, факторы прогноза.
Key words: castrate-resistant prostate cancer, chemotherapy, hormonal therapy, treatment algorithm, prognostic factors.
Ключевые слова: кастрационно-рефрактерный рак предстательной железы, химиотерапия, гормональная терапия, алгоритм лечения, факторы прогноза.
________________________________________________
Key words: castrate-resistant prostate cancer, chemotherapy, hormonal therapy, treatment algorithm, prognostic factors.
Полный текст
Список литературы
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.
2. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993; 118: 804–18.
3. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506–13.
4. European Association of Urology Guidelines. 2013 ed.; p. 133.
5. Oh W. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88: 3015–21.
6. Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? Semin Oncol 2013; 40 (3): 361–74.
7. Manni A, Bartholomew M, Caplan R et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6 (9): 1456–66.
8. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11 (11): 2167–72.
9. Hussain M, Wolf M, Marshall E et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12 (9): 1868–75.
10. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26: 3–7.
11. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448–53.
12. Kucuk O, Fisher E, Moinpour CM et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58 (1): 53–8.
13. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180 (3): 921–7.
14. European Association of Urology Guidelines. 2014 ed.; p. 155.
15. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (vers. 1.1). Eur J Cancer 2009; 45 (2): 228–47.
16. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944–9.
17. Haapala K, Hyytinen ER, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1674–51.
18. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11 (8): 1566–72.
19. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43 (3): 408–10.
20. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153 (6): 1946–7.
21. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP-17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26 (28): 4563–71.
22. Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP-17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27 (23): 3742–8.
23. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28 (9): 1496–501.
24. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP-17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28 (9): 1481–8.
25. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP-17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28 (9): 1489–95.
26. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995–2005.
27. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (2): 138–48.
28. Basch E, Autio K, Ryan CJ et al. Abiraterone acetate plus prednisone vs prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013; 14 (12): 1193–9.
29. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–12.
30. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376 (9747): 1147–54.
31. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47 (1): 8–32; http://10.1016/j.ejca.2010.10.013
32. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187–205.
33. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
34. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411–22.
35. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187–97.
36. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213–23.
37. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31 (4): 412–9.
38. Pili R, Häggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29 (30): 4022–8.
39. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
40. Oudard S et al. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39 (3): 275–89.
41. van Soest RJ, de Morrée ES, Shen L et al. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel. TAX327 Study. Eur Urol 2013; http://pii: S0302-2838(13)00828-2
42. Fizazi K, Flaig Th, Carsten H et al. Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials. Poster presented at the 2014 Genitourinary Cancers Symposium (ASCO GU). San Francisco 2014, CA.
2. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993; 118: 804–18.
3. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506–13.
4. European Association of Urology Guidelines. 2013 ed.; p. 133.
5. Oh W. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88: 3015–21.
6. Hoffman-Censits J, Fu M. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? Semin Oncol 2013; 40 (3): 361–74.
7. Manni A, Bartholomew M, Caplan R et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6 (9): 1456–66.
8. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11 (11): 2167–72.
9. Hussain M, Wolf M, Marshall E et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12 (9): 1868–75.
10. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26: 3–7.
11. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448–53.
12. Kucuk O, Fisher E, Moinpour CM et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58 (1): 53–8.
13. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180 (3): 921–7.
14. European Association of Urology Guidelines. 2014 ed.; p. 155.
15. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (vers. 1.1). Eur J Cancer 2009; 45 (2): 228–47.
16. Marcelli M, Ittmann M, Mariani S et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944–9.
17. Haapala K, Hyytinen ER, Roiha M et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1674–51.
18. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11 (8): 1566–72.
19. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43 (3): 408–10.
20. Dawson NA, McLeod DG. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153 (6): 1946–7.
21. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP-17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26 (28): 4563–71.
22. Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP-17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27 (23): 3742–8.
23. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28 (9): 1496–501.
24. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP-17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28 (9): 1481–8.
25. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP-17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28 (9): 1489–95.
26. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995–2005.
27. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368 (2): 138–48.
28. Basch E, Autio K, Ryan CJ et al. Abiraterone acetate plus prednisone vs prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013; 14 (12): 1193–9.
29. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–12.
30. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376 (9747): 1147–54.
31. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47 (1): 8–32; http://10.1016/j.ejca.2010.10.013
32. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187–205.
33. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
34. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411–22.
35. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187–97.
36. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369 (3): 213–23.
37. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31 (4): 412–9.
38. Pili R, Häggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011; 29 (30): 4022–8.
39. Loriot et al. J Clin Oncol 2012; 30 (Suppl. 5): Abstr. 213.
40. Oudard S et al. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39 (3): 275–89.
41. van Soest RJ, de Morrée ES, Shen L et al. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel. TAX327 Study. Eur Urol 2013; http://pii: S0302-2838(13)00828-2
42. Fizazi K, Flaig Th, Carsten H et al. Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials. Poster presented at the 2014 Genitourinary Cancers Symposium (ASCO GU). San Francisco 2014, CA.
Авторы
Б.Я.Алексеев, К.М.Нюшко, А.С.Калпинский, А.Д.Каприн
ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России
ФГБУ Московский научно-исследовательский онкологический институт им. П.А.Герцена Минздрава России
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.